Ibiden is overpriced and set to lose market share, so AT&S, Kinsus and Ajinomoto are the better substrate positions. This runs against FundaAI (@FundaAI), which argues that high-end ABF capacity is failing to keep pace with AI silicon and sees rerating room for Ibiden at about 45 times FY3/28 earnings. x.com







